Bristol-Myers Squibb Company is among the 12 Cheap Healthcare Stocks to Buy Now, specializing in oncology, immunology, cardiovascular, hematology, and neuroscience therapies. In July 2025, BMY partnered with Bain Capital to launch a new biotech focused on autoimmune disease therapies with $300 million in funding. BMY is advancing immunotherapy for lung cancer and launched a clinical trial for a breast cancer therapy in July 2025. Despite new initiatives, BMY maintains strong revenue from established products like Eliquis and Opdivo. BMY is also leveraging artificial intelligence for drug discovery and clinical trial efficiency.

In September 2025, BMY and BioNTech reported promising Phase II results for a lung cancer therapy, achieving a 76% tumor reduction rate. The therapy is now in Phase III trials valued at up to $11.1 billion. In addition, updated Phase I data for a PRMT5 inhibitor in non-small cell lung cancer showed a 29% response rate. Despite the potential of BMY as an investment, certain AI stocks may offer greater upside potential and carry less downside risk.

Read more at Yahoo Finance: Bristol-Myers Squibb Company (BMY)-BioNTech Lung Cancer Therapy Shows 76% Tumor Reduction